Aligos Therapeutics, Inc. (ALGS) operating margin
Aligos Therapeutics, Inc. (ALGS) had an operating margin of -4024.9% in fiscal 2025 (the year ended December 31, 2025). That is 1765.0 percentage points lower than the -2259.9% of fiscal 2024. Figures as of 17 Nov 2026, 17:35 UTC, from the company's filings with the SEC and Yahoo Finance.
Key facts
- Operating margin, fiscal 2025
- -4024.9%
- Change on fiscal 2024
- −1765.0 pts
- Highest on record
- -567.5%fiscal 2023
- Lowest on record
- -4024.9%fiscal 2025
- Fiscal years on record
- 42022–2025
Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Figures, not advice.
Aligos Therapeutics, Inc. operating margin, in more detail
Across the 4 fiscal years on record (2022–2025), the highest was -567.5% in fiscal 2023 and the lowest -4024.9% in fiscal 2025. The fiscal 2025 figure is no higher than in any of the 3 earlier fiscal years on record, whose median is -701.7%.
Net margin was -1106.7% in fiscal 2025.
Operating margin by fiscal year
- Operating margin
- Net margin
Aligos Therapeutics, Inc. operating margin, year by year
| Fiscal year | Operating margin | Change | Year ended | Net margin |
|---|---|---|---|---|
| 2025 | -4024.9% | 1765.0 pts down | -1106.7% | |
| 2024 | -2259.9% | 1692.4 pts down | -3326.0% | |
| 2023 | -567.5% | 134.2 pts up | -564.6% | |
| 2022 | -701.7% | — | -690.6% |
Change is on the fiscal year before, in percentage points; a dash means that year is not on record. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.
How it is calculated
Operating margin is operating income divided by revenue; gross margin does the same with gross profit, and net margin with net income.
How to read it
It shows how much of each unit of sales survives the cost of running the business — rising margins point to pricing power or scale, falling ones to pressure.
Aligos Therapeutics, Inc., figure by figure
- Aligos Therapeutics, Inc. market cap
- Aligos Therapeutics, Inc. revenue
- Aligos Therapeutics, Inc. earnings
- Aligos Therapeutics, Inc. earnings per share (EPS)
- Aligos Therapeutics, Inc. P/E ratio
- Aligos Therapeutics, Inc. P/S ratio
- Aligos Therapeutics, Inc. P/B ratio
- Aligos Therapeutics, Inc. free cash flow
- Aligos Therapeutics, Inc. dividend
- Aligos Therapeutics, Inc. shares outstanding
- Aligos Therapeutics, Inc. total debt
- Aligos Therapeutics, Inc. cash on hand
- Aligos Therapeutics, Inc. total assets
- Aligos Therapeutics, Inc. return on equity (ROE)
- Aligos Therapeutics, Inc. return on invested capital (ROIC)
Aligos Therapeutics, Inc. (ALGS) overview: price, valuation and scorecard
Aligos Therapeutics, Inc. operating margin: questions and answers
What is Aligos Therapeutics, Inc.'s operating margin?
Aligos Therapeutics, Inc. (ALGS) had an operating margin of -4024.9% in fiscal 2025 (the year ended December 31, 2025). That is 1765.0 percentage points lower than the -2259.9% of fiscal 2024.
Is Aligos Therapeutics, Inc.'s operating margin high or low compared with its own history?
The fiscal 2025 figure is no higher than in any of the 3 earlier fiscal years on record, whose median is -701.7%.
What are the highest and lowest operating margin figures on record for Aligos Therapeutics, Inc.?
Across the 4 fiscal years on record (2022–2025), the highest was -567.5% in fiscal 2023 and the lowest -4024.9% in fiscal 2025.
What are Aligos Therapeutics, Inc.'s gross and net margins?
Net margin was -1106.7% in fiscal 2025.
How is Aligos Therapeutics, Inc.'s operating margin calculated?
Operating margin is operating income divided by revenue; gross margin does the same with gross profit, and net margin with net income.
Fiscal years are named for the calendar year they end in.
Learn: operating margin
All stocks guides →- Revenue vs earnings vs free cash flow: what each tells you
Revenue is everything a company sold in a period. Earnings, or net income, is what remains after every cost, interest and tax. Free cash flow is the cash operations brought in minus spending on long-lived assets. Revenue shows size and demand, earnings show profitability, and free cash flow shows how much cash the business can actually hand out.
- Altman Z-score: formula, zones and where it fails
The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
- Analyst price targets and ratings: what they mean
An analyst price target is a research analyst's estimate of where a share price will be at a set horizon, such as twelve months; a rating such as buy or hold is that analyst's recommendation. A consensus is an average or median of the targets a data provider has collected. Studies have found targets on average well above later prices.
Cite this page
Funkfolio, “Aligos Therapeutics, Inc. (ALGS) operating margin”, data as of 17 November 2026. https://funkfolio.com/stock/ALGS/operating-margin
Underlying data: the company's filings with the SEC and Yahoo Finance.